Karolinska Development initiates collaborations with Ospedale San Raffaele and Medical University of Graz

STOCKHOLM – June 27, 2013. Two more world class research centers are teaming up
with Karolinska Development. Deal flow agreements have been signed with the
Italian university hospital Ospedale San Raffaele and the Medical University of
Graz in Austria, which enable Karolinska Development to identify investment
opportunities among life science innovations emanating from these leading
medical research institutions.
Karolinska Development will assist in the evaluation and assessment of new
innovations from each institution, and has the opportunity to invest in
commercially attractive projects. The institutions will benefit from Karolinska
Development’s drug and device development expertise and will be offered
engagement in any companies created from the collaborations.

“The deal flow agreements with Ospedale San Raffaele and the Medical University
of Graz will increase our access to new cutting-edge research projects and thus
gives us a broader base of potential investment opportunities. Further, the
collaboration underpins the international reputation of Karolinska Development
as an investor in the life science sector and as a developer of innovative new
treatments", said Torbjörn Bjerke, CEO of Karolinska Development.

Similar deal flow agreements are already established with, among others,
Karolinska Institutet in Sweden and Mayo Clinic in the US.

Ospedale San Raffaele is one of the leading research institutions in Europe. The
Italian university hospital is the highest ranking Italian biomedical research
institute with about 760 research scientists and 680 clinical researchers
working at translational programs, engaged in basic and clinical research within
gene therapy, stem cells, immunology, neurodegenerative diseases, proteomics,
bioinformatics, neurobiology, molecular biology and diabetes. In 2012, Ospedale
San Raffaele was involved in more than 700 clinical studies including about
9,500 patients.

The Medical University of Graz is conducting training, education and research at
world-class level, focusing on continuous improvement of top quality medicine
and surgery. The university is well renowned for its orientation toward the
biopsychosocial model. It has enabled approximately 1,480 researchers to work on
almost 3,000 research projects and includes three Nobel laureates amongst its
alumni.

For further information, please contact:
Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com

Robin Wright, CFO, Karolinska Development AB
Phone: +44 (0)7720 30 00 25, e-mail: robin.wright@karolinskadevelopment.com

Benjamin Nordin, IRO, Karolinska Development AB
Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development
AB

Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class science into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP innovations
to the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out-licensing of
products. An exclusive deal flow agreement with Karolinska Institutet
Innovations AB, along with other cooperation agreements with leading Nordic
universities, delivers a continuous flow of innovations. Today, the portfolio
consists of 38 projects, of which 16 are in clinical development. For more
information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.